Home
HelpTest ID: BAMRP Bile Acids Malabsorption Panel, Serum and Feces
Ordering Guidance
This test is for evaluation of bowel dysfunction.
For evaluation of hepatobiliary dysfunction, order BILEA / Bile Acids, Total, Serum.
For evaluation of patients treated with urso or cholate, order BAFS / Bile Acids, Fractionated and Total, Serum.
For evaluation of inborn errors of metabolism, order BAIPD / Bile Acids for Peroxisomal Disorders, Serum.
For confirmatory testing for bile acid malabsorption using a 48-hour fecal collection, order BA48F / Bile Acids, Bowel Dysfunction, 48 Hour, Feces
Shipping Instructions
Feces and serum should be shipped together. Specimens shipped separately may delay testing.
Specimen Required
Patient Preparation:
1. For serum collection: Patient must fast for at least 12 hours prior to collection; fasting morning specimen is preferred.
2. Patient should not have recently taken antibiotics, bile acid sequestrants for 24 hours prior to collection, or statins for 5 days prior to collection.
3. No laxatives (particularly mineral oil and castor oil)
4. No synthetic fat substitutes (eg, Olestra) or fat-blocking nutritional supplements
5. Barium interferes with test procedure; if patient has used barium, it is recommended to wait 48 hours before starting the stool collection.
Both feces and serum are required.
Collection for both serum and feces should be completed on the same day, but up to 3 days apart is acceptable.
Specimen Type: Serum
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Centrifuge and aliquot 1 mL of serum into a plastic vial.
2. Send specimen frozen.
Specimen Type: Feces
Supplies: Stool Container, Small (Random), 4 oz (T288)
Container/Tube: Fecal container
Specimen Volume: 5 g
Collection Instructions:
1. Collect a loose, unpreserved, random fecal specimen.
2. Freeze immediately.
Additional Information: If additional tests are ordered, aliquot and separate sample prior to freezing to allow 1 container per test.
Useful For
Aiding in the evaluation of patients suspected of having chronic diarrhea symptoms due to bile acid malabsorption
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| 7AC4 | 7AC4, Bile Acid Synthesis, S | Yes | Yes |
| BAMRF | Bile Acid, Malabsorption, F | No | Yes |
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Bile Acid Malabsorption PanelSpecimen Type
FecalSerum
Specimen Minimum Volume
Feces: See Specimen Collection
Homogenized feces: 1 mL
Serum: 0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Fecal | Frozen | 30 days | |
| Serum | Frozen (preferred) | 90 days | |
| Refrigerated | 72 hours | ||
| Ambient | 24 hours |
Clinical Information
Bile acids are synthesized from cholesterol in the liver and released into the digestive tract where they function to emulsify dietary fats and facilitate lipid absorption in the small intestine. The majority of bile acids are reabsorbed in the ileum of the healthy individual, with only 5% excreted in feces.(1)
The synthesis of bile acids in the liver is regulated by a negative feedback mechanism from the bile acids reabsorbed from the intestine. 7Alpha-hydroxy-4-cholesten-3-one (7aC4) is an intermediate in the biosynthesis pathway of cholesterol to bile acids. Primary bile acids cholic acid (CA) and chenodeoxycholic acid (CDCA) are deconjugated and dehydroxylated via intestinal bacteria into secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA), respectively.(2) The sum of CA, CDCA, DCA, LCA, and ursodeoxycholic acid composes the majority of bile acids in the feces. The concentration of 7aC4 in serum is a surrogate for the amount of bile acid synthesis in the liver. There is some diurnal variation in 7aC4 serum concentrations, so measurement should be performed on a fasting morning sample.
Patients with increased bile acid in their stool suffer from chronic diarrhea, termed bile acid diarrhea (BAD). Approximately 10% to 33% of patients with irritable bowel syndrome with diarrhea (IBS-D) have BAD. Additionally, BAD has been identified as a contributor of diarrhea in other conditions such as irritable bowel disease, Celiac disease, microscopic colitis, and neuroendocrine tumors.(3) Identifying patients with BAD can be done by measuring total and fractionated bile acids in stool. The increased bile acids in feces can be caused by an inability to reabsorb bile acids in the terminal ileum. The loss of intestinal reabsorption leads to increase synthesis of bile acids in the liver. Recent studies have shown that serum concentrations of 7aC4 are elevated in patients with BAD. Several intestinal diseases or functional abnormalities can lead to BAD. Identification of these patients can influence treatment decisions that could include the use of bile acid sequestrants. Conversely, patients with IBS with constipation (IBS-C) may have lower circulating 7aC4 as compared to healthy individuals.
The definitive test in the United States for BAD is the 48-hour stool bile acids test (BA48F / Bile Acids, Bowel Dysfunction, 48 Hour, Feces). However, given the challenge of a 48-hour specimen collection, a random stool collection can be used in combination with the results from serum 7aC4 testing. From a random stool collection, only the percentage of primary bile acids can be reported. Internal studies have shown that a combination of serum 7aC4 result above 52.5 ng/mL and primary fecal bile acid result above 10% is 66% sensitive and 95% specific for bile acid malabsorption.(4)
Quantitation of fecal bile acids aids in screening for BAD and identifying patients with chronic diarrhea who may benefit from bile acid sequestrant therapy.
Reference Values
BILE ACID MALABSORPTION, FECAL:
≥18 years:
Sum of cholic acid and chenodeoxycholic acid: ≤10.0%
7AC4, BILE ACID SYNTHESIS, SERUM:
2.5-63.2 ng/mL
Reference values have not been established for patients who are younger than 18 years of age.
Interpretation
When serum 7alpha-hydroxy-4-cholesten-3-one results are above 52.5 ng/mL and primary fecal bile acid results are above 10%, this test is 66% sensitive and 95% specific for bile acid malabsorption.
Pharmacological treatment with bile acid sequestrants has been shown to improve symptoms in some patients.
Clinical Reference
1. Vijayvargiya P, Camilleri M, Chedid V, et al. Analysis of fecal primary bile acids detects increased stool weight and colonic transit in patients with chronic functional diarrhea. Clin Gastroenterol Hepatol. 2019 Apr;17(5):922-929.e2
2. Vijayvargiya P, Camilleri M: Current practice in the diagnosis of bile acid diarrhea. Gastroenterology. 2019;156:(5):1233-1238
3. Vijayvargiya P, Gonzalez Izundegui D, Calderon G, et al. Increased fecal bile acid excretion in a significant subset of patients with other inflammatory diarrheal diseases. Dig Dis Sci. 2022;67(6):2413-2419. doi:10.1007/s10620-021-06993-5
4. Vijayvargiya P, Camilleri M, Taylor A, Busciglio I, Loftus EV Jr, Donato LJ: Combined fasting serum C4 and primary bile acids from a single stool sample to diagnose bile acid diarrhea. Gastroenterology. 2020 Nov;159(5):1952-1954.e2
5. Duboc H, Rainteau D, Rajca S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012;24(6):513-520, e246-7
6. Vijayvargiya P, Camilleri M, Shin A, Saenger A. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol. 2013;11(10):1232-1239
7. Vijayvargiya P, Camilleri M, Carlson P, et al. Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea. Aliment Pharmacol Ther. 2017;46(6):581-588. doi:10.1111/apt.14214
8. Camilleri M, Nadeau A, Tremaine WJ, et al. Measurement of serum 7 alpha-hydroxy-4-cholesten-3-one (or 7AC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil. 2009;21(7):734-743
9. Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2012;10(9):1009-1015.e3
Day(s) Performed
Wednesday
Report Available
2 to 9 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82542 x2
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| BAMRP | Bile Acid Malabsorption Panel | 104027-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 65504 | 7AC4, Bile Acid Synthesis, S | 94866-1 |
| 620308 | Bile Acids, % CDCA + CA, F | 103710-0 |
| 619971 | Bile Acid Malabsorption Panel Interpretation | 59462-2 |
Testing Algorithm
For more information see Bile Acid-Associated Tests Ordering Guide.
Forms
If not ordering electronically, complete, print, and send a Gastroenterology and Hepatology Test Request (T728) with the specimen.